NEW YORK (GenomeWeb News) – Leukocare and Trillium Diagnostics today announced a deal to develop and market Leukocare's method for detecting inflammatory activity using circulating cell-free DNA.

Trillium will use the method to develop a commercial assay for diagnosing sepsis, they said. Under the terms of the deal, Leukocare grants Trillium an exclusive, royalty-bearing license to its patent covering the technology and know-how for measuring the quantity of cf-DNA to develop a commercial in vitro diagnostic assay.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.